HTLV infection in persons with sexually transmitted diseases in Spain

Multicenter cross-sectional study of HTLV-1 prevalence and associated risk factors in epidemiologically relevant groups across Brazil

Background

Human T cell lymphotropic virus type 1 (HTLV-1) is highly endemic in Brazil, necessitating surveillance studies to understand its epidemiology. While previous research has focused on either specific cities or populations, there is a need for multicenter studies encompassing epidemiologically relevant populations to ascertain more accurate prevalence rates and predictors of HTLV-1 infection in the country.

Methods

We conducted a multicenter, cross-sectional study involving 3,184 participants across seven cities and five study populations in Brazil. Blood samples were collected, and the prevalence of HTLV-1 infection was determined by enzyme-linked immunosorbent assay (ELISA) and Western blot. Binary logistic regression analysis was used to determine risk factors of HTLV-1 infection.

Results

Among the total study population, 1,135 (35.7%) were aged >40 years and 1,704 (53.5%) were female. The overall prevalence of HTLV-1 infection was 0.5% (95% CI: 0.3-0.8), with variation observed among the cities or study populations. Factors associated with HTLV-1 infection included age > 40 years (OR, 8.867; 95% CI: 1.824-43.099), female gender (OR, 4.604; 95% CI: 1.184-17.903), and Hepatitis C virus (HCV) infection (OR, 13.995; 95% CI: 2.374-82.506). The identification of older age and female gender, coupled with the high prevalence of HTLV-1 in HIV-positive patients, suggests sexual transmission as the primary route of HTLV-1 infection.

Conclusion

Our study reveals varied prevalence rates of HTLV-1 infection across diverse populations and cities in Brazil. The association of older age, female gender, and HCV, emphasizes the need for tailored interventions to prevent HTLV-1 transmission.

Prevalence of HTLV-1/2 infection in pregnant women in Central and South America and the Caribbean: a systematic review and meta-analysis

BACKGROUND

Human T-lymphotropic viruses (HTLV)-1 infection is endemic in many countries of Central and South America and Caribbean (CSA&C). Neither screening nor surveillance programs exist for HTLV-1/2 infection among pregnant women in this region. Neither in Western nations with large migrant flows from HTLV-1/2 endemic regions.

METHODS

Systematic review and meta-analysis of the prevalence of HTLV-1/2 infection among CSA&C pregnant women. We included studies searching EMBASE, PubMed/MEDLINE, Scopus, and Web of Science from inception to February 15, 2023. This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines.

RESULTS

We identified a total of 620 studies. Only 41 were finally included in the meta-analysis. Most studies (61.0%) were from Brazil and Peru (14.6%). The total number of participants was 343,707. The pooled prevalence of HTLV-1/2 infection among CSA&C pregnant women was 1.30% (95% CI: 0.96-1.69) using anti-HTLV-1/2 antibody screening tests. There was a high heterogeneity (I2 = 98.6%). Confirmatory tests gave an HTLV-1 infection rate of 1.02% (95% CI: 0.75-1.33).

CONCLUSIONS

The prevalence of HTLV-1/2 infection among CSA&C pregnant women is 1.3%, most cases being HTLV-1. This rate is greater than for other microbial agents regularly checked as part of antenatal screening (such as HIV, hepatitis B, or syphilis). Thus, HTLV-1/2 antenatal testing should be mandatory among CSA&C pregnant women everywhere.

Screening for HTLV-1 infection should be expanded in Europe

Human T-cell lymphotropic virus type 1 (HTLV-1) infection is spreading globally at an uncertain speed. Sexual, mother-to-child, and parenteral exposure are the major transmission routes. Neither vaccines nor antivirals have been developed to confront HTLV-1, despite infecting over 10 million people globally and causing life-threatening illnesses in 10% of carriers. It is time to place this long-neglected disease firmly into the 2030 elimination agenda. Current evidence supports once-in-life testing for HTLV-1, as recommended for HIV, hepatitis B and C, along with targeted screening of pregnant women, blood donors, and people who attended clinics for sexually transmitted infections (STIs). Similar targeted screening strategies are already being performed for Chagas disease in some Western countries in persons from Latin America. Given the high risk of rapid-onset HTLV-1-associated myelopathy, universal screening of solid organ donors is warranted. To minimize organ wastage, however, the specificity of HTLV screening tests must be improved. HTLV screening of organ donors in Europe has become mandatory in Spain and the United Kingdom. The advent of HTLV point-of-care kits would facilitate testing. Finally, increasing awareness of HTLV-1 will help those living with HTLV-1 to be tested, clinically monitored, and informed about transmission-preventive measures.